March 26, 2018 / 11:51 AM / 6 months ago

BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer

March 26 (Reuters) - Heat Biologics Inc:

* HEAT BIOLOGICS - REPORTS 2 YEAR DATA FROM PHASE 2 TRIAL OF HS-410 COMBINED WITH BACILLUS CALMETTE-GUÉRIN FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER

* HEAT BIOLOGICS - WITHIN SUBGROUP OF PATIENTS WHO RECEIVED LOW DOSE OF CO'S IMPACT HS-410 WITH BCG, 10 OUT OF 10 REMAINED DISEASE FREE AFTER 2-YRS Source text: (bit.ly/2pGwsuk) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below